14th International Congress on Autoimmunity 2024
Sebia booth #15
The next generation instrument for screening hemoglobin disorders in newborns.
European Myeloma Network Meeting – EMN 2024
Sebia booth: #9
Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.
Educational Workshop with Dr. Barbara De la Salle
Learn more about the HYDRASYS 2 SCAN FOCUSING for a fast and user-friendly gel electrophoresis processing.
Autoinmunidad y Cáncer : aproximación inteligente al diagnóstico y tratamiento de enfermedades derivadas de las células plasmáticas
Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma